Genor Biopharma Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2007-12-04
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genorbio.com
Phase â… Clinical Study Protocol of GB223 Monoclonal Antibody Injection
Phase 1
- Conditions
- Bone Tumor
- Interventions
- Biological: GB223,119mg/kgBiological: GB223,140mg/kgBiological: GB223,21mg/kgBiological: GB223,63mg/kgBiological: GB223,7mg/kg
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT04178044
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.
Phase 1
- Conditions
- Brain Tumor
- Interventions
- Biological: GB222 3mg/kgBiological: GB222 5mg/kgBiological: GB222 7.5mg/kgBiological: GB222 10mg/kg
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04178057
- Locations
- 🇨🇳
Beijing Tiantan Hospital of Capital Medical University, Beijing, Beijing, China
Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection
Phase 3
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: GB242Biological: Infliximab
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 568
- Registration Number
- NCT04178850
- Locations
- 🇨🇳
Peking University People Hospital, Beijing, Beijing, China
Clinical Trial in Chinese Healthy Volunteers of GB222
Phase 1
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: GB222Biological: Bevacizumab
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04175158
- Locations
- 🇨🇳
People's Hospital of Peking University, Beijing, Beijing, China
Clinical Trial of Comparative Study of GB221 Pharmacokinetics
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04175171
- Locations
- 🇦🇺
Linear Clinical Research Limited, Nedlands, Western Australia, Australia
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Phase 1
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Biological: GB221,2 mg/kgBiological: GB221,6 mg/kgBiological: Herceptin,6 mg/kgBiological: GB221,8mg/kg
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT04170595
- Locations
- 🇨🇳
Affiliated Hospital of Academy of Military Medical Sciences, Beijing, Beijing, China
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT04164615
- Locations
- 🇨🇳
People's Liberation Army General Hospital The Fifth Medical Center, Beijing, Beijing, China
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
Phase 1
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT03977090
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03976856
- Locations
- 🇨🇳
Shanghai chest hospital, Shanghai, Shanghai, China
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
Phase 2
- Conditions
- Cervical Cancer
- Interventions
- Biological: GB226
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT03808857
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath